D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder

CNS Spectrums

Volumn 19, Issue 2, 2014, Pages 176-181

  Potkin, Steven G ^a   Keator, David B ^a   Kesler West, Marilyn L ^a   Nguyen, Dana D ^a   Van Erp, Theo G M ^a   Mukherjee, Jogeshwar ^a   Shah, Nikunj ^a   Preda, Adrian ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

brain imaging; Lurasidone; Occupancy; PET; schizoaffective; Schizophrenia

Indexed keywords

DOPAMINE 2 RECEPTOR; DRUG METABOLITE; FALLYPRIDE F 18; LURASIDONE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; N-((1-ALLYL-2-PYRROLIDINYL)METHYL)-5-(3-FLUOROPROPYL)-2,3-DIMETHOXYBENZAMIDE; BENZAMIDE DERIVATIVE; DIAGNOSTIC AGENT; ISOINDOLE DERIVATIVE; N ((1 ALLYL 2 PYRROLIDINYL)METHYL) 5 (3 FLUOROPROPYL) 2,3 DIMETHOXYBENZAMIDE; NEUROLEPTIC AGENT; PYRROLIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; ARTICLE; BRAIN CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DSM-IV; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MENTAL HEALTH CARE; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RECEPTOR OCCUPANCY; REPEATED DRUG DOSE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; STEADY STATE; ALGORITHM; BRAIN; DRUG EFFECT; METABOLISM; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; SCINTISCANNING; STATISTICS; YOUNG ADULT;

ADULT; ALGORITHMS; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; ISOINDOLES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; PYRROLIDINES; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; STATISTICS AS TOPIC; THIAZOLES; YOUNG ADULT;

EID: 84901698821     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S109285291300059X     Document Type: Article

References (27)

1. Mukherjee J, Yang ZY, Brown T, et al. Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride. Nucl Med Biol. 1999; 26(5): 519-527. (Pubitemid 29378486)
2. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: A double-blind, placebocontrolled trial. J Clin Psychiatry. 2009; 70(6): 829-836.
3. Meyer JM, Loebel AD, Schweizer E. Lurasidone: A new drug in development for schizophrenia. Expert Opin Investig Drugs. 2009; 18(11): 1715-1726.
4. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010; 334(1): 171-181.
5. Tarazi FI, Stahl SM. Iloperidone, asenapine and lurasidone: A primer on their current status. Expert Opin Pharmacother. 2012; 13(13): 1911-1922.
6. Mukherjee J, Christian BT, Dunigan KA, et al. Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse. 2002; 46(3): 170-188. (Pubitemid 35155170)
7. Nordstrom AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993; 33(4): 227-235. (Pubitemid 23091497)
8. Citrome L. Lurasidone for schizophrenia: A review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011; 65(2): 189-210.
9. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: A randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011; 168(9): 957-967.
10. Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and activecontrolled trial. Schizophr Res. 2013; 145(1-3): 101-109.
11. Koo TS, Kim SJ, Lee J, et al. Quantification of lurasidone, an atypical antipsychotic drug, in rat plasma with high-performance liquid chromatography with tandem mass spectrometry. Biomed Chromatogr. 2011; 25(12): 1389-1394.
12. Chouinard G, Margolese HC. Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res. 2005; 76(2-3): 247-265. (Pubitemid 40804771)
13. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134(4): 382-389. (Pubitemid 9136500)
14. Guy W. Clinical Global Impression Scale: The ECDEU Assessment Manual for Psychopharmacology-Revised. Volume DHEW, Publ. No. ADM 76, 1976; Vol. 338: 218-222.
15. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261-276. (Pubitemid 18039085)
16. Sossi V, de Jong HWAM, Barker WC, et al. The second generation HRRT-A multi-centre scanner performance investigation. In: Nuclear Science Symposium Conference Record, 2005. New York: IEEE; 2005: 2195-2199. (Pubitemid 46172186)
17. Hong IK, Chung ST, Kim HK, et al. Fast forward projection and backward projection algorithm using SIMD. In: Nuclear Science Symposium Conference Record, 2006. New York: IEEE; 2006: 3361-3368.
18. Hong I, Burbar Z, Michel C. True 3D iterative scatter correction for small bore long axial FOV scanner. In: Nuclear Science Symposium and Medical Imaging Conference (NSS/MIC), 2011. New York: IEEE; 2011: 3736-3738.
19. Logan JFowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996; 16(5): 834-840. (Pubitemid 26292051)
20. Wong DF, Kuwabara H, Brašić JR, et al. Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacology (Berl). In press. DOI: 10.1007/s00213-013-3103-z.
21. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000; 157(4): 514-520. (Pubitemid 30191189)
22. Farde L, Wiesel FA, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry. 1988; 45(1): 71-76. (Pubitemid 18018572)
23. Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004; 161(5): 818-825. (Pubitemid 38625334)
24. Grunder G, Landvogt C, Vernaleken I, et al. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology. 2005; 31(5): 1027-1035.
25. Grunder G, Fellows C, Janouschek H, et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F] fallypride PET study. Am J Psychiatry. 2008; 165(8): 988-995.
26. Rahmioglu N, Heaton J, Clement G, et al. Genetic epidemiology of induced CYP3A4 activity. Pharmacogenet Genomics. 2011; 21(10): 642-651.
27. Pinborg LH, Videbaek C, Ziebell M, et al. [123I]epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: Implications for the use of cerebellum as a reference region. Neuroimage. 2007; 34(4): 1450-1453. (Pubitemid 46201908)